Physician profile
Sheldon S Stoffer
NPI 1801897814
$3,935.71
in general payments reported to CMS, 2019-2025
35 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $122 · 2021: $89.75 · 2022: $575 · 2023: $1,186 · 2024: $955 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.09 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $502.52 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.15 | 2021-2025 | Jardiance, Ofev |
| Abbott Laboratories | $295.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $274.83 | 2021-2023 | |
| Amgen INC. | $272.80 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $247.26 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $178.40 | 2022-2025 | Unithroid |
| Lilly USA, LLC | $173.02 | 2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $167.96 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $137.26 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $131.66 | 2019-2025 | Farxiga |
| Exact Sciences Corporation | $124.22 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $55.84 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $48.20 | 2024 | Gvoke Hypopen |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $36.25 | 2019-2023 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $35.33 | 2024-2025 | Opsumit, Uptravi |
| Shield Therapeutics INC | $31.99 | 2022-2023 | Accrufer |
| Vanda Pharmaceuticals INC. | $30.78 | 2023 | Hetlioz |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2022 | |
| Ascendis Pharma Endocrinology INC | $29.30 | 2023 | |
| Pfizer INC. | $24.10 | 2019 | |
| Dynavax Technologies Corporation | $23.74 | 2024-2025 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $22.21 | 2025 | Evkeeza |
| Optinose US, INC. | $20.19 | 2024 | |
| Azurity Pharmaceuticals, INC. | $17.82 | 2023 | Edarbi |
| Pulmonx Corporation | $16.06 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Promius Pharma LLC | $15.46 | 2019 | |
| Esperion Therapeutics, INC. | $15.13 | 2023 | Nexletol |
| Dexcom, INC. | $14.45 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $14.21 | 2025 | Shingrix, Bexsero |
| Ibsa Pharma INC. | $14.09 | 2023 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $13.33 | 2023 | Contrave |
| Shire North American Group INC | $13.07 | 2019 | |
| Amarin Pharma, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Stoffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.